The deal was first announced in September. Intracept will be added to Boston Scientific’s chronic pain portfolio that includes spinal cord stimulation, radiofrequency ablation and an interspinous spacer procedure. Intracept recently earned national coverage from Anthem Blue Cross Blue Shield and Humana
The transaction includes an upfromt cash payment of $850 million and contingent payments based on sales over three years.
